60 Degrees Pharmaceuticals, Inc. (SXTP) Revenue History
Annual and quarterly revenue from 2020 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SXTP Revenue Growth
SXTP Revenue Analysis (2020–2024)
As of May 8, 2026, 60 Degrees Pharmaceuticals, Inc. (SXTP) generated trailing twelve-month (TTM) revenue of $963,526, reflecting explosive growth of +223.4% year-over-year. The most recent quarter (Q3 2025) recorded $437,602 in revenue, up 333.6% sequentially.
Looking at the longer-term picture, SXTP's historical revenue data shows a 3-year CAGR of -19.4%. The company achieved its highest annual revenue of $2.2 million in 2020.
When compared to Healthcare sector peers including AEYE (+14.5% YoY), GERN (+68.6% YoY), and NUVB (+1205.5% YoY), SXTP has underperformed the peer group in terms of revenue growth. Compare SXTP vs AEYE →
SXTP Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SXTPCurrent | $963,526 | +223.4% | - | -1599.0% | |
 AEYE | $40M | +14.5% | +14.5% | -7.9% | |
 GERN | $184M | +68.6% | +273.5% | -29.3% | |
 NUVB | $63M | +1205.5% | - | -338.7% | |
 HALO | $1.4B | +37.6% | +39.2% | 58.4% |
SXTP Historical Revenue Data (2020–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $608K | +139.6% | $223K | 36.7% | $-9,714,931 | -1599.0% |
| 2023 | $254K | +13.6% | $-220,977 | -87.1% | $-5,154,583 | -2032.8% |
| 2022 | $223K | -80.8% | $-209,162 | -93.7% | $-1,750,445 | -784.2% |
| 2021 | $1.2M | -46.8% | $310K | 26.7% | $-1,124,102 | -96.9% |
| 2020 | $2.2M | - | $1.5M | 67.8% | $-418,130 | -19.2% |
See SXTP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SXTP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SXTP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSXTP — Frequently Asked Questions
Quick answers to the most common questions about buying SXTP stock.
Is SXTP's revenue growth accelerating or slowing?
SXTP revenue is accelerating at +223.4% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $963526.00. Growth momentum has increased versus prior periods.
What is SXTP's long-term revenue growth rate?
60 Degrees Pharmaceuticals, Inc.'s 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +223.4% is above this long-term average.
How is SXTP's revenue distributed by segment?
SXTP reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2024 are available for download. Segment mix reveals concentration and diversification trends.